Calidi Biotherapeutics (NYSE:CLDI) Shares Up 4.1% – Still a Buy?

Calidi Biotherapeutics, Inc. (NYSE:CLDI)’s share price shot up 4.1% on Thursday . The stock traded as high as $1.30 and last traded at $1.26. 495,336 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 2,139,222 shares. The stock had previously closed at $1.21.

Calidi Biotherapeutics Stock Down 16.7 %

The firm’s 50 day moving average is $1.17 and its two-hundred day moving average is $1.37.

Hedge Funds Weigh In On Calidi Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in Calidi Biotherapeutics by 35.5% in the fourth quarter. Millennium Management LLC now owns 136,137 shares of the company’s stock valued at $157,000 after buying an additional 35,637 shares during the period. Jane Street Group LLC acquired a new position in Calidi Biotherapeutics in the fourth quarter valued at $38,000. Geode Capital Management LLC lifted its holdings in Calidi Biotherapeutics by 304.0% in the fourth quarter. Geode Capital Management LLC now owns 160,018 shares of the company’s stock valued at $184,000 after buying an additional 120,406 shares during the period. Virtu Financial LLC acquired a new position in Calidi Biotherapeutics in the fourth quarter valued at $84,000. Finally, RS Crum Inc. acquired a new position in Calidi Biotherapeutics in the fourth quarter valued at $47,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.